Roche Bullish Despite Biosimilars Battering
Pharma Sales Down By 7% in Q4
Executive Summary
Its older oncology products are sinking but the Swiss major is confident about coming through COVID-19 in a strong position.
You may also be interested in...
Roche Takes Advantage Of COVID-19 Testing Rush
Roche’s sales in 2020 increased by 1%, at constant exchange rates, to CHF 58.3bn, led by 14% growth in its diagnostics division.
Don’t Write Actemra Off Yet: Roche Drug Found To Be Lifesaving In COVID-19
After failing in five earlier trials, Actemra shows significant life-saving benefits for patients with severe COVID-19.
Bayer Ponders Road Less Traveled And Trip Savings In Pandemic
Like most CEOs in pharma, Bayer chief Werner Baumann was constantly on the move but "since the middle to the end of the first quarter last year, I haven't traveled at all."
Need a specific report? 1000+ reports available
Buy Reports